High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma.
Mucin-7 is a member of the secreted mucins family. Mucins might play a crucial role during tumor development and its aberrant expression was observed in several types of tumor. Our study aims to evaluate the prognostic significance of Mucin-7 expression in postoperative clear-cell renal cell carcinoma (ccRCC) patients. In this retrospective study, we enrolled 392 patients with ccRCC undergoing nephrectomy between 2008 and 2009 in a single center. The median follow-up was 73 months (range 39-74 months). Mucin-7 expression was evaluated by immunohistochemistry protocol on ccRCC specimens. Kaplan-Meier survival analysis was conducted to compare survival curves. Univariate and multivariate Cox regression models were applied to assess the impact of prognostic factors in overall survival (OS) and recurrence-free survival (RFS). A nomogram was then constructed based on the independent prognosticators identified on multivariate analysis. The results displayed that Mucin-7 expression was significantly associated with tumor size (p = 0.034), pT stage (p = 0.004), TNM stage (p = 0.008), and necrosis (p = 0.043). Patients with high Mucin-7 expression had significant worse outcomes in both OS (p < 0.001) and RFS (p < 0.001) compared to those with low Mucin-7 expression. MUC7 expression was considered as an independent predictive factor for OS (HR 2.286; 95 %CI 1.167-4.475; p = 0.016) and RFS (HR 2.055; 95 %CI 1.086-3.887; p = 0.027). A nomogram integrating Mucin-7 expression and other independent prognosticators was constructed. In summary, the high Mucin-7 expression is a potential prognosticator of adverse clinical outcome in ccRCC patients after surgery.
Department of Urology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
SonTung
S
NguyenHoang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China.
Yidong
Y
Liu
Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Le
L
Xu
Department of Urology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Yuan
Y
Chang
Department of Urology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Lin
L
Zhou
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China.
Zheng
Z
Liu
Department of Urology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zongminglin@gmail.com.
Zongming
Z
Lin
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Mailbox 103, 138 Yixueyuan Road, Shanghai, 200032, China. jjxufdu@fudan.edu.cn.
Jiejie
J
Xu
D014408:Biomarkers, Tumor / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000556:secondary* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism*; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D009367:Neoplasm Staging; D009392:Nephrectomy; D011379:Prognosis; D012189:Retrospective Studies; D012471:Salivary Proteins and Peptides / Q000378:metabolism*; D015996:Survival Rate
D014408:Biomarkers, Tumor; C083238:MUC7 protein, human; D009077:Mucins; D012471:Salivary Proteins and Peptides
Clear-cell renal cell carcinoma; Mucin-7; Overall survival; Prognostic biomarker; Recurrence-free survival
Ann Surg Oncol. 2014 Sep;21(9):3142-50
24615178
J Urol. 2003 Jan;169(1):86-9
12478110
Lancet. 2009 Mar 28;373(9669):1119-32
19269025
J Urol. 2006 Apr;175(4):1235-9
16515968
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):183-94
26558360
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
15534099
J Gastrointest Surg. 1997 Mar-Apr;1(2):106-12
9834336
Cancer Biomark. 2010;9(1-6):461-73
22112490
Mol Cancer. 2014 May 29;13:129
24886523
Biochim Biophys Acta. 2015 Dec;1856(2):211-25
26318196
Nat Rev Cancer. 2004 Jan;4(1):45-60
14681689
Eur Urol. 2004 Mar;45(3):314-9
15036676
J Oral Microbiol. 2015 Dec 22;7:29759
26701274
Ann Surg Oncol. 2010 Jun;17(6):1471-4
20180029
Am J Pathol. 1999 Aug;155(2):461-72
10433939
J Urol. 2002 Dec;168(6):2395-400
12441925
J Clin Oncol. 2004 Aug 15;22(16):3316-22
15310775
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):E866-75
24550497
Eur J Cancer. 2004 Mar;40(4):481-6
14962712
J Urol. 2012 Mar;187(3):834-9
22245331
Cancer. 2003 Apr 1;97(7):1663-71
12655523
Nat Rev Cancer. 2009 Dec;9(12):874-85
19935676
Histopathology. 2002 May;40(5):450-7
12010365